Skip to product information
1 of 1

Elabscience

SKU:PKSH032238

Recombinant Human CEACAM7/CGM2 Protein (His Tag)

Recombinant Human CEACAM7/CGM2 Protein (His Tag)

Regular price $178.00 USD
Regular price Sale price $178.00 USD
Sale Sold out
Shipping calculated at checkout.
Size
Introducing the Recombinant Human CEACAM7/CGM2 Protein (HIS TAG), a meticulously engineered product that showcases exceptional quality and efficacy. This protein, derived from human CEACAM7/CGM2, is produced using advanced recombinant technology, ensuring utmost purity and consistency.

The inclusion of the HIS tag in this protein facilitates easy purification and detection, making it an ideal choice for various research applications. With its high affinity for metal ions, the HIS tag enables efficient immobilization and subsequent isolation of the protein, simplifying experimental procedures.

Our Recombinant Human CEACAM7/CGM2 Protein (HIS TAG) exhibits remarkable stability and solubility, guaranteeing optimal performance in diverse experimental settings. Its precise amino acid sequence, derived from the human CEACAM7/CGM2 gene, ensures accurate representation of the native protein, enabling reliable and reproducible results.

This product is meticulously manufactured in a state-of-the-art facility, adhering to stringent quality control measures. Each batch undergoes rigorous testing to ensure its integrity, purity, and functionality, providing researchers with utmost confidence in their experiments.

The Recombinant Human CEACAM7/CGM2 Protein (HIS TAG) is an indispensable tool for studying CEACAM7/CGM2-related processes, such as cell adhesion, immune response, and tumor development. Its versatility extends to applications in drug discovery, protein-protein interaction studies, and diagnostic assay development.

Choose the Recombinant Human CEACAM7/CGM2 Protein (HIS TAG) for its exceptional quality, reliability, and ease of use. Elevate your research endeavors with this cutting-edge protein, designed to empower scientists and drive scientific progress.
View full details